公开(公告)号：US20240238310A1

公开(公告)日：2024-07-18

申请号：US18434367

申请日：2024-02-06

Applicant: Northwestern University

Inventor： Serdar E. Bulun ,  Hong Zhao

IPC: A61K31/5685 ,  A61F2/00 ,  A61K9/00 ,  A61K31/4196 ,  A61K31/4535 ,  A61K31/56 ,  A61K31/566 ,  A61P43/00

CPC classification number: A61K31/5685 ,  A61F2/0063 ,  A61K9/0014 ,  A61K9/0019 ,  A61K9/0053 ,  A61K31/4196 ,  A61K31/4535 ,  A61K31/56 ,  A61K31/566 ,  A61P43/00 ,  A61F2250/0067

Abstract: Disclosed are methods and compositions for treating and/or preventing hernias in subjects in need thereof. The disclosed methods of treatment and/or preventing may include methods for treating and/or preventing hernias in subject in need thereof by administering to the subject a therapeutic agent that modulates sex steroid hormone production and/or activity in the subject. Hernias treated and/or prevented by the disclosed methods may include, but are not limited to, inguinal hernias, femoral hernias, umbilical hernias, hiatal hernias, incisional hernias, and diastasis recti.

公开(公告)号：US20240082213A1

公开(公告)日：2024-03-14

申请号：US18516541

申请日：2023-11-21

Applicant: Nexyon Biotech Co., Ltd.

Inventor： Jung Taek Seo ,  Seok Jun Moon ,  Sung-Jin Kim

IPC: A61K31/37 ,  A61K31/404 ,  A61K31/473 ,  A61K31/5377 ,  A61K31/56 ,  A61K31/568 ,  A61K31/5685 ,  A61K31/662 ,  A61P1/16 ,  A61P3/04 ,  A61P3/10

CPC classification number: A61K31/37 ,  A61K31/404 ,  A61K31/473 ,  A61K31/5377 ,  A61K31/56 ,  A61K31/568 ,  A61K31/5685 ,  A61K31/662 ,  A61P1/16 ,  A61P3/04 ,  A61P3/10

Abstract: The present disclosure relates to a functional composition for the prevention, amelioration or treatment of obesity or lipid-related metabolic disorders, which comprises a steroid sulfatase inhibitor as an active ingredient.

公开(公告)号：US20230398085A1

公开(公告)日：2023-12-14

申请号：US18457567

申请日：2023-08-29

Applicant: Duke University

Inventor： Suzanne E. Wardell ,  Erik R. Nelson ,  Donald P. McDonnell

IPC: A61K31/137 ,  A61K9/00 ,  A61K31/136 ,  A61K31/138 ,  A61K31/40 ,  A61K31/4196 ,  A61K31/4535 ,  A61K31/565 ,  A61K31/5685 ,  A61K45/06 ,  C07C217/78 ,  C07C217/84

CPC classification number: A61K31/137 ,  A61K9/0019 ,  A61K31/136 ,  A61K31/138 ,  A61K31/40 ,  A61K31/4196 ,  A61K31/4535 ,  A61K31/565 ,  A61K31/5685 ,  A61K45/06 ,  C07C217/78 ,  C07C217/84 ,  A61K2121/00

Abstract: Disclosed herein are methods of treating subjects suffering from estrogen receptor positive cancer of the brain by administering a selective estrogen receptor degrader (SERM). Also disclosed are methods of treating a cancer that is resistant to an estrogen receptor modulator by administering a SERM.

公开(公告)号：US20230293548A1

公开(公告)日：2023-09-21

申请号：US18150870

申请日：2023-01-06

Applicant: Windtree Therapeutics, Inc.

Inventor： Giuseppe Bianchi ,  Patrizia Ferrari ,  Mara Ferrandi ,  Paolo Barassi

IPC: A61K31/5685 ,  A61P9/06 ,  A61P9/04 ,  A61K9/00

CPC classification number: A61K31/5685 ,  A61P9/06 ,  A61P9/04 ,  A61K9/009

Abstract: Compositions for intravenous infusion of istaroxime, or a metabolite of istaroxime, in human patients suffering from heart failure are disclosed. Likewise, methods for extended infusion of istaroxime or its metabolites in individuals with heart failure are disclosed. In particular, some methods disclosed herein include the infusion of istaroxime, or a metabolite thereof, for a period of time that is greater than six hours in order to improve cardiac relaxation without triggering arrhythmogenic events in an individual suffering from heart failure. Other methods include administration of istaroxime until certain plasma concentration thresholds of istaroxime metabolites are achieved. Also disclosed are istaroxime metabolites with selective SERCA2a activation.

公开(公告)号：US20230285276A1

公开(公告)日：2023-09-14

申请号：US18171409

申请日：2023-02-20

Applicant: Celanese EVA Performance Polymers LLC

Inventor： Jeffrey Haley ,  Vijay Gyanani ,  Karen Chen ,  Thomas Quinci ,  Brian Wilson

IPC: A61K9/00 ,  A61K31/5685 ,  A61K47/32 ,  A61K45/06 ,  A61K9/48

CPC classification number: A61K9/0024 ,  A61K31/5685 ,  A61K47/32 ,  A61K45/06 ,  A61K9/4816

Abstract: An implantable medical device is provided. The core includes a core polymer matrix within which is dispersed a therapeutic agent comprising one or more aromatase inhibitors. The core polymer matrix contains an ethylene vinyl acetate copolymer. The ethylene vinyl acetate copolymer has a melting temperature of from about 40° C. to about 120° C. as determined in accordance with ASTM D3418-15.

公开(公告)号：US11685762B2

公开(公告)日：2023-06-27

申请号：US17098307

申请日：2020-11-13

Applicant: SD Chem, Inc.

Inventor： Yu Ge

IPC: C07J1/00 ,  A61K9/00 ,  A61K31/5685 ,  A61P1/00 ,  A61P31/06 ,  A61P37/06 ,  A61P3/10 ,  A61P35/00 ,  A61K9/19 ,  A61K47/34 ,  A61K47/38 ,  A61P11/06

CPC classification number: C07J1/0011 ,  A61K9/0019 ,  A61K9/19 ,  A61K31/5685 ,  A61K47/34 ,  A61K47/38 ,  A61P1/00 ,  A61P3/10 ,  A61P11/06 ,  A61P31/06 ,  A61P35/00 ,  A61P37/06

Abstract: Method of treating a subject in need of a treatment for modulating immune system or anti-microbial infection, comprising administering a stable aqueous suspension formulation, which may be reconstituted from a water dispersible dry composition, comprising compound of Formula I in the form of particles stabilized in an aqueous suspension. It causes little or no injection site irritation and has superior properties over non-aqueous formulations. It stimulates autophagy, enhance innate immunity, down-regulates unproductive inflammation and exerts a Th1 immune bias. It demonstrates better efficacy in both in vitro and in vivo models.

公开(公告)号：US11648222B2

公开(公告)日：2023-05-16

申请号：US17136428

申请日：2020-12-29

Applicant: Io Therapeutics, Inc. ,  The Johns Hopkins University

Inventor： Gabriel Ghiaur ,  Richard J. Jones ,  Salvador Alonso ,  Roshantha A. Chandraratna

IPC: A61K31/196 ,  A61K45/06 ,  A61K31/192 ,  A61K31/4166 ,  A61K31/454 ,  A61K31/4196 ,  A61K31/138 ,  A61K31/58 ,  A61K31/4545 ,  A61K31/5685 ,  A61K31/277 ,  A61P35/00 ,  A61K31/69

CPC classification number: A61K31/196 ,  A61K31/138 ,  A61K31/192 ,  A61K31/277 ,  A61K31/4166 ,  A61K31/4196 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/5685 ,  A61K31/58 ,  A61K31/69 ,  A61K45/06 ,  A61P35/00 ,  A61K31/192 ,  A61K2300/00 ,  A61K31/196 ,  A61K2300/00 ,  A61K31/138 ,  A61K2300/00 ,  A61K31/277 ,  A61K2300/00 ,  A61K31/4196 ,  A61K2300/00 ,  A61K31/4166 ,  A61K2300/00 ,  A61K31/454 ,  A61K2300/00 ,  A61K31/4545 ,  A61K2300/00 ,  A61K31/5685 ,  A61K2300/00 ,  A61K31/58 ,  A61K2300/00

Abstract: Disclosed herein are methods for treating a cancer comprising administering to a subject in need thereof an effective dose of a CYP26-resistant retinoic acid receptor (RAR) alpha (RARα) selective agonist, whereby as a result of the treatment the tumor burden is reduced in the subject and cancer stem cells resident in the bone marrow are substantially reduced.

公开(公告)号：US20230144197A1

公开(公告)日：2023-05-11

申请号：US17785511

申请日：2020-12-16

Applicant: CARRICK THERAPEUTICS LIMITED

Inventor： Edward AINSCOW ,  Ashwani BAHL ,  Mihiro SUNOSE ,  Damien Francis Philippe CREPIN ,  Kamaldeep Kaur CHOHAN ,  Brett STEVENSON ,  Jason John SHIERS

IPC: C07D519/00 ,  C07D487/04 ,  A61K31/519 ,  A61K31/5685 ,  A61K31/4196 ,  A61K31/568 ,  A61K31/138 ,  A61K31/167 ,  A61K31/4166 ,  A61K31/4184 ,  A61K39/395 ,  C07K16/32 ,  A61K31/517 ,  A61K31/337 ,  A61K31/664 ,  A61K31/282 ,  A61K31/7068 ,  A61K31/704 ,  A61K31/513

CPC classification number: C07D519/00 ,  C07D487/04 ,  A61K31/519 ,  A61K31/5685 ,  A61K31/4196 ,  A61K31/568 ,  A61K31/138 ,  A61K31/167 ,  A61K31/4166 ,  A61K31/4184 ,  A61K39/39558 ,  C07K16/32 ,  A61K31/517 ,  A61K31/337 ,  A61K31/664 ,  A61K31/282 ,  A61K31/7068 ,  A61K31/704 ,  A61K31/513

Abstract: The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain H-APPAMP compounds (referred to herein as “H-APPAMP compounds”) that, inter alia, inhibit cyclin-dependent protein kinases (CDKs), especially CDK12 and/or CDK13, and are selective, for example, for CDK12 and/or CDK13 as compared to CDK7. In addition to selectively inhibiting CDK12 and/or CDK13, the compounds also act as selective Cyclin K degraders thereby removing the key signaling mechanism required for CDK12 and/or CDK13 activation; this confers additional cellular potency and selectivity. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CDK, especially CDK12 and/or CDK13; and to treat disorders including: disorders that are associated with CDK, especially CDK12 and/or CDK13; disorders that result from an inappropriate activity of a CDK, especially CDK12 and/or CDK13; disorders that are associated with CDK mutation, especially CDK12 and/or CDK13 mutation; disorders that are associated with CDK overexpression, especially CDK12 and/or CDK13 overexpression; disorders that are associated with upstream pathway activation of CDK, especially CDK12 and/or CDK13; disorders that are ameliorated by the inhibition of CDK, especially CDK12 and/or CDK13; proliferative disorders; cancer; viral infections (including HIV); neurodegenerative disorders (including Alzheimer's disease and Parkinson's disease); ischaemia; renal diseases; cardiovascular disorders (including atherosclerosis); autoimmune disorders (including rheumatoid arthritis); and disorders caused by dysfunction of translation in cells (including muscular dystrophy). Optionally, the treatment further comprises treatment (e.g., simultaneous or sequential treatment) with a further active agent which is, e.g., an aromatase inhibitor, an anti estrogen, an anti-androgen, a Her2 blocker, a cytotoxic chemotherapeutic agent, an agent stimulating the immune system, a checkpoint inhibitor, a DNA repair inhibitor, etc.

公开(公告)号：US20180071314A1

公开(公告)日：2018-03-15

申请号：US15706341

申请日：2017-09-15

Applicant: ACCELERATED GENETIX, LLC

Inventor： John Dunlop ,  Dongdong Chen

IPC: A61K31/5685 ,  A61K9/00 ,  A61K9/14

CPC classification number: A61K31/5685 ,  A61K9/0053 ,  A61K9/141 ,  A61K31/568 ,  A61K45/06 ,  A61K2300/00 ,  A61P5/00 ,  A61P15/00

Abstract: A method of promoting muscle growth consisting of providing a dietary supplement containing an effective amount of dehydroandrosterol to a user. A composition for promoting muscle growth containing an effective amount of dehydroandrosterol.

公开(公告)号：US20180071313A1

公开(公告)日：2018-03-15

申请号：US15563108

申请日：2016-04-01

Applicant: SANTEN PHARMACEUTICAL CO., LTD.

Inventor： Kenichi ENDO ,  Shinobu FUJII ,  Kenji OKI

IPC: A61K31/5685 ,  A61K31/565 ,  A61K9/00 ,  A61K9/06

CPC classification number: A61K31/5685 ,  A61K9/0048 ,  A61K9/06 ,  A61K31/565

Abstract: An object of the present invention is to provide a novel dry eye therapeutic agent that demonstrates superior dry eye therapeutic effects, and from the viewpoint of the drug administration burden of the patient, is capable of demonstrating a medicinal effect over a long period of time in lacrimal gland tissue after the administration thereof.A dry eye therapeutic agent comprising nandrolone or an ester thereof or methenolone or an ester thereof is therapeutically effective on dry eye since it increases the amount of tear lipocalin (TL) in tears, and medicinal effects can be demonstrated over a long period of time in lacrimal gland tissue by administering a dry eye therapeutic agent comprising nandrolone or an ester thereof or methenolone or an ester thereof to eyelid skin.